PRKDC and breast carcinoma: A similar study using MDA-MB-231 breast cancer cells demonstrated that downregulation of DNA-PK using shRNA resulted in greater cisplatin sensitivity, confirming that DNA-PK plays a role in acquired resistance to cisplatin [166].